RECENT ADVANCEMENTS IN PYRIDINE DERIVATIVES AS ANTICANCER AGENTS

Pyridine derivatives are a structurally heterogeneous and pharmacologically important class of compounds with increasing importance in anticancer drug development. Their unique electronic profile, synthetic tractability, and high biological activity allow targeted modulation of critical molecular pathways implicated in cancer advancement. Recent developments are the discovery of pyridine-urea hybrids, fused heterocycles like pyrazolopyridines and thienopyridines, and hybrid pharmacophores, many of which have shown significant cytotoxicity against a broad spectrum of cancer cell lines with increased selectivity and fewer off-target effects. Mechanistic studies have shown their efficacy in inhibiting VEGFR-2- induced angiogenesis, HDAC inhibition, and tumor-associated enzyme-selective inhibition of human carbonic anhydrase IX and XII. These results have been buttressed by computational methods including molecular docking and SAR analysis, which enable rational drug design and optimization. Despite their promise, numerous challenges remain—such as systemic toxicity, poor selectivity, drug resistance, poor solubility, and synthesis complexity—that limit their clinical applicability. In an effort to overcome these challenges, scientists are investigating nanotechnology-based drug delivery systems, covalent inhibitor design, and environmentally friendly synthesis strategies for improving bioavailability and therapeutic index. Notable examples, including Linifanib and SLC-0111, have reached clinical trials, demonstrating the translational potential of this compound class. Further interdisciplinarity research to overcome current shortcomings will only serve to reinforce the position of pyridine derivatives in contemporary oncology as leading contenders for next-generation anticancer therapy.